| RRC ID |
78802
|
| 著者 |
Motonari T, Yoshino Y, Haruta M, Endo S, Sasaki S, Miyashita M, Tada H, Watanabe G, Kaneko T, Ishida T, Chiba N.
|
| タイトル |
Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.
|
| ジャーナル |
Sci Rep
|
| Abstract |
Homologous recombination (HR) repairs DNA damage including DNA double-stranded breaks and alterations in HR-related genes results in HR deficiency. Germline alteration of HR-related genes, such as BRCA1 and BRCA2, causes hereditary breast and ovarian cancer (HBOC). Cancer cells with HR deficiency are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors and DNA-damaging agents. Thus, accurately evaluating HR activity is useful for diagnosing HBOC and predicting the therapeutic effects of anti-cancer agents. Previously, we developed an assay for site-specific HR activity (ASHRA) that can quantitatively evaluate HR activity and detect moderate HR deficiency. HR activity in cells measured by ASHRA correlates with sensitivity to the PARP inhibitor, olaparib. In this study, we applied ASHRA to lymphoblastoid cells and xenograft tumor tissues, which simulate peripheral blood lymphocytes and tumor tissues, respectively, as clinically available samples. We showed that ASHRA could be used to detect HR deficiency in lymphoblastoid cells derived from a BRCA1 pathogenic variant carrier. Furthermore, ASHRA could quantitatively measure the HR activity in xenograft tumor tissues with HR activity that was gradually suppressed by inducible BRCA1 knockdown. The HR activity of xenograft tumor tissues quantitatively correlated with the effect of olaparib. Our data suggest that ASHRA could be a useful assay for diagnosing HBOC and predicting the efficacy of PARP inhibitors.
|
| 巻・号 |
14(1)
|
| ページ |
7519
|
| 公開日 |
2024-4-8
|
| DOI |
10.1038/s41598-024-57367-6
|
| PII |
10.1038/s41598-024-57367-6
|
| PMID |
38589490
|
| PMC |
PMC11001962
|
| MeSH |
Antineoplastic Agents* / pharmacology
BRCA1 Protein / genetics
Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
DNA / therapeutic use
Female
Homologous Recombination
Humans
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / genetics
Phthalazines / pharmacology
Phthalazines / therapeutic use
Piperazines*
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Poly(ADP-ribose) Polymerases / genetics
|
| リソース情報 |
| ヒト・動物細胞 |
HEV0012(HEV0012)
277-LCL(RCB2283) |
